Authors:
Metz, JM
Jones, H
Devine, P
Hahn, S
Glatstein, E
Citation: Jm. Metz et al., Cancer patients use unconventional medical therapies far more frequently than standard history and physical examination suggest, CANCER J, 7(2), 2001, pp. 149-154
Citation: E. Glatstein, As good as it gets - Training with Henry Kaplan and Saul Rosenberg during the Stanford studies on Hodgkin's disease and lymphoma, CANC BIO R, 16(4), 2001, pp. 269-273
Authors:
Hendren, SK
Hahn, SM
Spitz, FR
Bauer, TW
Rubin, SC
Zhu, T
Glatstein, E
Fraker, DL
Citation: Sk. Hendren et al., Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors, ANN SURG O, 8(1), 2001, pp. 65-71
Authors:
Machtay, M
Lee, JH
Shrager, JB
Kaiser, LR
Glatstein, E
Citation: M. Machtay et al., Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma, J CL ONCOL, 19(19), 2001, pp. 3912-3917
Citation: E. Glatstein, In regard to Glatstein: Scientific physicians and evidence-based medicine.IJROBP 2001;49 : 619-621 - In Response, INT J RAD O, 50(5), 2001, pp. 1375-1375
Citation: Jm. Metz et E. Glatstein, Local control versus systemic control: Is the cart coming before the oncologic horse?, CANCER J, 6(2), 2000, pp. 66-68
Authors:
Vulcan, TG
Zhu, TC
Rodriguez, CE
Hsi, A
Fraker, DL
Baas, P
Murrer, LHP
Star, WM
Glatstein, E
Yodh, AG
Hahn, SM
Citation: Tg. Vulcan et al., Comparison between isotropic and nonisotropic dosimetry systems during intraperitoneal photodynamic therapy, LASER SURG, 26(3), 2000, pp. 292-301
Citation: Ra. Hsi et E. Glatstein, Re-resection with brachytherapy for locally recurrent soft tissue sarcoma:Is there a leg to stand on?, CA J SCI AM, 5(1), 1999, pp. 18-19
Authors:
Moore, HCF
Mick, R
Solin, LJ
Sickles, C
Mangan, PA
Luger, SM
Fox, KR
Schuchter, LM
Loh, E
Porter, DL
Schuster, S
Buzby, GP
Glatstein, E
Silberstein, LE
Stadtmauer, EA
Citation: Hcf. Moore et al., Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: Impact on the delivery of local-regional radiation therapy, ANN ONCOL, 10(8), 1999, pp. 929-936
Citation: E. Glatstein, Dr. Strange (high) tech or how I learned to stop worrying and love my MLC/3D treatment planning, stereotactic linac, INT J RAD O, 45(5), 1999, pp. 1097-1101